Trinity compound research profile
IGF-1 DES
IGF-1 DES (full name des(1-3)IGF-I) is a naturally occurring, shortened version of a hormone called IGF-1 (insulin-like growth factor 1) — one of the main...
Research overview
IGF-1 DES (full name des(1-3)IGF-I) is a naturally occurring, shortened version of a hormone called IGF-1 (insulin-like growth factor 1) — one of the main hormones your body uses to actually build muscle and tissue once growth hormone has done its job. This shortened version is simply missing the first three building blocks (amino acids) off the front of the chain. It's been found naturally in cow's first milk (colostrum), human brain tissue, and pig tissue, and scientists believe the body itself creates it by clipping a piece off regular IGF-1, rather than it being a totally separate hormone (Ballard et al. 1996).
Mechanism under study
Regular IGF-1 usually travels through your blood "handcuffed" to escort proteins (called IGFBPs) that control how much of it is actually free to work on cells at any given time. Because IGF-1 DES is missing those first three building blocks, it slips out of the escort proteins' grip much more easily. This means more of it stays "free" and active at any given moment, which is why it appears roughly 10 times more powerful than regular IGF-1 in lab-dish tests — not because it binds any differently to the actual receptor, but because more of it is available and unrestrained (Ballard et al. 1996).
Human evidence summary
There is no human research on this peptide at all. The scientific paper describing it specifically said that possible medical uses in people had not even been evaluated yet (Ballard et al. 1996). Any claims you might see about it building muscle, targeting specific body areas, or healing injuries in humans are not backed by any human study — they are theoretical or purely anecdotal.
Preclinical evidence summary
In lab-dish tests, IGF-1 DES was about 10 times more potent than regular IGF-1 at causing cells to grow and multiply, because it escapes the escort proteins that normally hold IGF-1 back (Ballard et al. 1996). In marmoset monkeys and pigs, IGF-1 DES and related engineered versions were confirmed to be more potent than regular IGF-1, but this extra potency came with a serious catch: it caused 4 to 8 times more low blood sugar (hypoglycemia) than an equal amount of regular IGF-1, and this low blood sugar effect lasted longer even though the drug itself left the bloodstream faster (Tomas et al. 1997).
Source material
Use the linked publications and records to evaluate study design, population, limitations, and relevance.